Huaren Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 37.3329 million yuan, a year-on-year decrease of 49.01%
Huaren Pharmaceutical released its semi-annual report for 2025, with operating revenue of 624 million yuan, a year-on-year decrease of 19.13%; net profit attributable to the parent company of 37.3329 million yuan, a year-on-year decrease of 49.01%; net profit excluding non-recurring gains and losses of 27.6892 million yuan, a year-on-year decrease of 59.17%; basic earnings per share of 0.0316 yuan
According to the Zhitong Finance APP, Huaren Pharmaceutical (300110.SZ) released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 624 million yuan, a year-on-year decrease of 19.13%. The net profit attributable to shareholders of the listed company was 37.3329 million yuan, a year-on-year decrease of 49.01%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 27.6892 million yuan, a year-on-year decrease of 59.17%. The basic earnings per share were 0.0316 yuan
